Observer access is free for approved healthcare, research, biopharma, regulatory, and capital professionals. Build a public professional profile, receive verified signal briefings, and become visible inside the AimwellBio intelligence network. LinkedIn shows where you've been. AimwellBio shows what you're qualified to notice.
“How would your professional credibility change if the fields you watch were publicly visible on a verified, peer-reviewed intelligence profile?”
Observer is the front door, not a trial. It’s a standing seat in a credentialed community — better than a profile on a research network, because every member is verified before they’re visible. What’s active for you now, and what opens as you go deeper:
Generate up to 5 source-traced verdicts, read across AIMN:ATLAS (400+ confidence-scored biopharma entities), and publish a verified public profile once your credential review completes. These are delivered today.
Your curated signal feed, watchlist, and indication dossiers activate during onboarding as the signal engine ships. Until then, what you see below is a labeled Sample of the briefing format — not data drawn on your account yet.
Contributors, Members, and Signal-tier seats raise verdict volume and unlock the saved-work surfaces. The honest one-line comparison is below — pick the seat that matches how you actually work.
This is a Sample of the briefing format Observers receive once the signal feed activates during onboarding. It is illustrative — not data drawn on your account.
Submit signals and review claims alongside the FHIN cohort. The seat for Observers who want to shape the standard, not just watch it.
Become a Contributor →Higher verdict volume and the saved-work surfaces for individual practitioners who run decisions weekly, not occasionally.
See Member tier →Team-scale verdict volume and the watchlist, dossier, and competitor surfaces as they activate. For groups standing behind the same decisions.
See Signal tier →Command tier is sales-assisted — built with you, not bought off a checkout page. Request Command access →
The professionals who shape a field are rarely the ones who waited to be invited. Being an Observer is a position you take: visibly part of the network deciding what counts as verified before the rest of the field catches up.
These are the therapeutic areas with a curated AimwellBio signal corpus on disk today — counts and last-compiled dates read straight from the dataset, not asserted. Sources: PubMed, ClinicalTrials.gov, FDA, and SEC EDGAR. This is a scheduled-refresh, curated corpus — compiled on a schedule, not streamed.
Loading the curated corpus…
Oncology, Renal, Metabolic, Wound-Care, Neurology, Cardiovascular, ccRCC, Diabetes, and Rare-Disease. Open an indication on your profile to follow it; the curated corpus is sourced from PubMed, ClinicalTrials.gov, FDA, and SEC EDGAR.
Choose what you watch →One real entry from a curated oncology corpus, shown to demonstrate the source-chain layer Observers read. Dossier automation is in activation — this item is drawn from the dataset, traced to its public source.
A verified professional page that shows what you're watching — not just where you've worked. Shareable on LinkedIn, in email signatures, on publications.
Tag the indications and domains you actively track — Oncology, Rare Disease, AI in healthcare, FDA/regulatory, Gene Therapy, and more. Visible on your public profile.
Link LinkedIn, ORCID, Google Scholar, ResearchGate, PubMed, X, and YouTube in one verified profile. One canonical URL for your professional identity in biopharma.
Curated signals from PubMed, SEC EDGAR, ClinicalTrials.gov, and FDA events — source-traced, confidence-graded, and filtered by indication.
Full AIMN:ATLAS access: 400+ biopharma entities, confidence-scored. Quarterly methodology briefings on the Adversarial Validation Standard, before the field at large.
Active Observers who contribute verified signals over 90 days are invited into the FHIN Contributor Network — the next tier in the intelligence ladder.
Observer access is not for the general public, and AimwellBio does not pretend otherwise. Verification is the network’s value. Below is what credentialing looks like, not all categories require the same standard, but all require something that can be checked.
Submit the Observer application with your professional credentials. Takes ~5 minutes.
AimwellBio reviews every application personally. License + role verification against public registries. Typical turnaround: 48 hours.
Approved Observers receive a magic-link login + welcome briefing + their verifiable Member Status credential.
Full Observer dashboard access. Lifetime, free, no renewal. Your public profile goes live once your credential review is complete — profiles are not visible until verified.
Observers who contribute verified signals over 90 days are invited into the FHIN Contributor Network — the expert layer that challenges AI-generated science before it reaches decision-makers.
Every other intelligence tool sells access on a credit card. AimwellBio sells access on verification. The credential bar exists because the network’s third-party legitimacy depends on who’s in it, and the Charter the cohort holds AimwellBio to depends on the cohort being real practitioners. Free is the price. Verification is the cost. One scales the network. The other protects it.
How would your professional credibility change if your work was visibly part of a peer-vetted intelligence network?
Want to be a Contributor instead of an Observer? See /fhin →
Plus: Observer access includes Network Pulse, Atlas Read-Through, Signal Detail pages, and quarterly methodology briefings — lifetime free for approved professionals.
Hand us anything your team is about to use. We return a source-risk review with every citation traced. No sales call. No follow-up sequence. The review itself is the conversation.
Teams searched documents, reviewed guidance updates, followed trial movement, tracked competitors, and built internal briefs by hand. Slow but auditable. Every claim had a paper trail.
Speed. The same brief that took a week now takes minutes. The trade-off: unsupported claims, stale guidance, missing context, and incomplete summaries can now move into serious decisions before anyone challenges them.
AimwellBio is the verification layer that sits between AI-generated intelligence and the decision someone signs their name to. Source-trace, adversarial review, confidence labels, institutional memory.
Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows. Open to credentialed professionals. No sales sequence, no list-trading.